Is TCR2 Therapeutics Inc. (TCRR) A Good Stock To Buy ?

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of TCR2 Therapeutics Inc. (NASDAQ:TCRR).

TCR2 Therapeutics Inc. (NASDAQ:TCRR) has seen a decrease in hedge fund interest lately. Our calculations also showed that TCRR isn't among the 30 most popular stocks among hedge funds (see the video below).

5 Most Popular Stocks Among Hedge Funds
5 Most Popular Stocks Among Hedge Funds

Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

So, why do we pay attention to hedge fund sentiment before making any investment decisions? Our research has shown that hedge funds' small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the Russell 2000 ETFs by 40 percentage points since May 2014 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter. Even if you aren't comfortable with shorting stocks, you should at least avoid initiating long positions in stocks that are in our short portfolio.

[caption id="attachment_337892" align="aligncenter" width="2480"]

Lei Zhang Hillhouse Capital
Lei Zhang Hillhouse Capital

Lei Zhang of Hillhouse Capital Management[/caption]

We're going to take a look at the latest hedge fund action encompassing TCR2 Therapeutics Inc. (NASDAQ:TCRR).

Hedge fund activity in TCR2 Therapeutics Inc. (NASDAQ:TCRR)

At Q3's end, a total of 2 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -50% from the second quarter of 2019. By comparison, 0 hedge funds held shares or bullish call options in TCRR a year ago. So, let's see which hedge funds were among the top holders of the stock and which hedge funds were making big moves.